Inotuzumab ozogamicin is an antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide.
- Mechanism
- Curator reviewed · 11 references
Leukemic cells express several lineage-specific antigens, with CD22 being one of the most common antigens identified on the surface of mature and immature B cells.
Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (ADC) composed of a CD22-directed humanized monoclonal IgG4 antibody linked to a N-acetyl-gamma-calicheamicin, a DNA-binding cytotoxic agent, via a linker. The antibody portion of the drug binds to CD22-expressing tumour cells, leading to internalization of the drug-CD22 complex forming an endosome. The endosome fuses with lysosomes, causing the hydrolytic cleavage of the linker and the intracellular release of N-acetyl-gamma-calicheamicin into the cell. N-acetyl-gamma-calicheamicin binds to the minor groove of the DNA in a sequence-specific manner and induces double-strand DNA breaks in tumour cells, ultimately causing cell cycle arrest and apoptotic cell death.
- Primary indication
- In the US, inotuzumab ozogamicin is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one year and older.Curator reviewed · 4 structured indications
- First approval
- Canada, 2018 · United States, 2017 · European Union, 2020
- Code names
- CMC-544 · PF-05208773 · WAY-207294
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Inotuzumab ozogamicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account